Q-omics provides the consensus-scored TTC22 profile across patient tissues and cancer cell-line models. TTC22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC22 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TTC22 RNA expression shows 17,700 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where TTC22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC22 survival associations across molecular data types. TTC22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC22 RNA expression–survival associations across cancer types. High TTC22 expression shows unfavorable associations in LIHC and PAAD, but favorable associations in KIRC, COAD, MESO and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC22 RNA expression.
This table summarizes TTC22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTC22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC22 shows lower tumor expression in COAD, KICH and READ and higher tumor expression in LUAD, BLCA and LUSC. The COAD box plot shows higher TTC22 RNA expression in normal versus tumor tissue (log2 FC = −1.544, t-test p < 0.001).
This table shows molecular features associated with TTC22 in patient tissues and cancer cell lines. In patient samples, TTC22 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and URINARY_TRACT.
